Toll Free: 1-888-928-9744

Glaucoma - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 250 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Glaucoma - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Glaucoma - Pipeline Review, H1 2015', provides an overview of the Glaucoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Glaucoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Glaucoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Glaucoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Glaucoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Glaucoma Overview 11
Therapeutics Development 12
Pipeline Products for Glaucoma - Overview 12
Pipeline Products for Glaucoma - Comparative Analysis 13
Glaucoma - Therapeutics under Development by Companies 14
Glaucoma - Therapeutics under Investigation by Universities/Institutes 18
Glaucoma - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Glaucoma - Products under Development by Companies 23
Glaucoma - Products under Investigation by Universities/Institutes 29
Glaucoma - Companies Involved in Therapeutics Development 30
AC Immune SA 30
Acadia Pharmaceuticals Inc. 31
Aerie Pharmaceuticals, Inc. 32
Alcon, Inc. 33
Allergan, Inc. 34
Altacor Ltd. 35
Amakem NV 36
Asahi Kasei Pharma Corp. 37
AUS Bio Limited 38
Bausch & Lomb Incorporated 39
Bionure Farma, S.L. 40
Can-Fite BioPharma Ltd. 41
Cellular Biomedicine Group, Inc. 42
China Grand Wuhan General Pharmaceutical Research Institute 43
D. Western Therapeutics Institute, Inc. 44
DNAVEC Corporation 45
Dompe Farmaceutici S.p.A. 46
F. Hoffmann-La Roche Ltd. 47
Foamix Pharmaceuticals Ltd. 48
Gene Signal International SA 49
Gilead Sciences, Inc. 50
Handok Inc. 51
High Point Pharmaceuticals, LLC 52
Icon Bioscience, Inc. 53
IMMD Inc. 54
Inotek Pharmaceuticals Corporation 55
InSite Vision Incorporated 56
Lacer, S.A. 57
Merck & Co., Inc. 58
Merz Pharma GmbH & Co. KgaA 59
Mimetogen Pharmaceuticals Inc. 60
NeoStem, Inc. 61
Neurotech Pharmaceuticals, Inc. 62
NicOx S.A. 63
Ocata Therapeutics, Inc. 64
Ocular Therapeutix, Inc. 65
Ohr Pharmaceutical Inc. 66
Ono Pharmaceutical Co., Ltd. 67
Otsuka Holdings Co., Ltd. 68
Oxford BioMedica plc 69
PharmaNova Inc. 70
Quark Pharmaceuticals, Inc. 71
Santen Pharmaceutical Co., Ltd. 72
Senju Pharmaceutical Co., Ltd. 73
SIFI S.p.A 74
SK Biopharmaceuticals Co., Ltd. 75
Sun Pharma Advanced Research Company Ltd. 76
Sylentis S.A. 77
Teva Pharmaceutical Industries Limited 78
Upsher-Smith Laboratories, Inc. 79
Glaucoma - Therapeutics Assessment 80
Assessment by Monotherapy Products 80
Assessment by Combination Products 81
Assessment by Target 82
Assessment by Mechanism of Action 86
Assessment by Route of Administration 90
Assessment by Molecule Type 92
Drug Profiles 94
(AR-13324 + latanoprost) - Drug Profile 94
(bimatoprost + brimonidine tartrate) - Drug Profile 95
(carteolol hydrochloride + latanoprost) - Drug Profile 96
(dorzolamide hydrochloride + latanoprost) - Drug Profile 97
(latanoprost + trabodenoson) - Drug Profile 98
(Prostaglandin Agonist + Beta-Blocker) - Drug Profile 99
(tafluprost + timolol maleate) - Drug Profile 100
AC-262271 - Drug Profile 101
ACI-260 - Drug Profile 102
ACN-1052 - Drug Profile 103
aganirsen - Drug Profile 104
ALT-022 - Drug Profile 106
AMA-0076 - Drug Profile 107
Antibody to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile 108
AP-022 - Drug Profile 109
APH-1104 - Drug Profile 110
AR-13324 - Drug Profile 111
AR-13533 - Drug Profile 112
ATS-8535 - Drug Profile 113
BA-1049 - Drug Profile 114
BA-240 - Drug Profile 115
bimatoprost - Drug Profile 116
bimatoprost SR - Drug Profile 117
BN-201 - Drug Profile 118
CF-101 - Drug Profile 119
CNS-102 - Drug Profile 122
DE-117 - Drug Profile 123
dorzolamide hydrochloride nanoparticle - Drug Profile 124
Drugs for Steroid Induced Glaucoma - Drug Profile 125
Drugs to Inhibit Cadherin-5 for Glaucoma - Drug Profile 126
Drugs to Target Bestrophin-2 for Glaucoma - Drug Profile 127
ENV-515 - Drug Profile 128
GB-201 - Drug Profile 129
GB-202 - Drug Profile 130
GB-203 - Drug Profile 131
GB-204 - Drug Profile 132
Gene Therapy for Glaucoma and Retinitis Pigmentosa - Drug Profile 133
Gene Therapy for Ocular Diseases - Drug Profile 134
Gene Therapy for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile 135
Glaucoma-GT - Drug Profile 136
GS-607601 - Drug Profile 137
H-1129 - Drug Profile 138
H-1129 Backup - Drug Profile 139
HL-5521 - Drug Profile 140
HPP-851 - Drug Profile 141
IMD-1041 - Drug Profile 142
KR-12 - Drug Profile 143
LA-8045 - Drug Profile 144
latanoprost - Drug Profile 145
latanoprost - Drug Profile 146
latanoprost - Drug Profile 148
latanoprost - Drug Profile 149
latanoprost SR - Drug Profile 150
latanoprostene bunod - Drug Profile 152
lomerizine - Drug Profile 154
Lycium Anti-Angiogenic Proteoglycan - Drug Profile 155
MD-920G - Drug Profile 156
MIMD-3 - Drug Profile 157
minocycline Gel - Drug Profile 158
Monoclonal Antibody to Activate Bves for Glaucoma - Drug Profile 159
MRZ-99030 - Drug Profile 160
NB-1111 - Drug Profile 161
NCX-1021 - Drug Profile 162
NCX-250 - Drug Profile 163
Neurovitas - Drug Profile 164
NT-501 - Drug Profile 165
NT-509 - Drug Profile 167
ONO-9054 - Drug Profile 168
OPA-6566 - Drug Profile 169
PBF-695 - Drug Profile 170
PRX-00933 - Drug Profile 171
QPI-1007 - Drug Profile 172
R-807 - Drug Profile 173
Recombinant Human Nerve Growth Factor - Drug Profile 174
RO-5093151 - Drug Profile 175
SF-103 - Drug Profile 177
SF-108 - Drug Profile 178
SF-109 - Drug Profile 179
SF-116 - Drug Profile 180
SKL-G - Drug Profile 181
SKS-1002 - Drug Profile 182
Small Molecule for Glaucoma - Drug Profile 183
Small Molecule for Glaucoma - Drug Profile 184
Small Molecule to Inhibit Rho Kinase for Glaucoma - Drug Profile 185
Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile 186
Small Molecules for CNS Disorders and Ophthalmology - Drug Profile 187
Small Molecules to Activate sGC for Ophthalmology - Drug Profile 188
Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Drug Profile 189
Small Molecules to Antagonize TRPV4 for Glaucoma - Drug Profile 190
Small Molecules to Inhibit LIMK1 AND LIMK2 for Cancer and Ophthalmology - Drug Profile 191
SNJ-1656 - Drug Profile 192
SNJ-1945 - Drug Profile 194
Stem Cell Therapy for Glaucoma - Drug Profile 195
Stem Cell Therapy for Glaucoma, Cerebral Palsy and Lupus - Drug Profile 196
Stem Cell Therapy for Macular Degeneration and Glaucoma - Drug Profile 197
Stem Cell Therapy for Ophthalmic Disorders - Drug Profile 198
SYL-040012 - Drug Profile 199
Synthetic Peptide for Glaucoma - Drug Profile 201
tafluprost - Drug Profile 202
trabodenoson - Drug Profile 204
travoprost SR - Drug Profile 205
TRV-32R - Drug Profile 206
XY-0811QF2 - Drug Profile 207
XY-1303LT2 - Drug Profile 208
Glaucoma - Recent Pipeline Updates 209
Glaucoma - Dormant Projects 230
Glaucoma - Discontinued Products 232
Glaucoma - Product Development Milestones 233
Featured News & Press Releases 233
Appendix 242
Methodology 242
Coverage 242
Secondary Research 242
Primary Research 242
Expert Panel Validation 242
Contact Us 243
Disclaimer 243
List of Tables
Number of Products under Development for Glaucoma, H1 2015 19
Number of Products under Development for Glaucoma - Comparative Analysis, H1 2015 20
Number of Products under Development by Companies, H1 2015 21
Number of Products under Investigation by Universities/Institutes, H1 2015 25
Comparative Analysis by Late Stage Development, H1 2015 26
Comparative Analysis by Clinical Stage Development, H1 2015 27
Comparative Analysis by Early Stage Development, H1 2015 28
Comparative Analysis by Unknown Stage Development, H1 2015 29
Products under Development by Companies, H1 2015 30
Products under Development by Companies, H1 2015 (Contd..1) 31
Products under Development by Companies, H1 2015 (Contd..2) 32
Products under Development by Companies, H1 2015 (Contd..3) 33
Products under Development by Companies, H1 2015 (Contd..4) 34
Products under Development by Companies, H1 2015 (Contd..5) 35
Products under Investigation by Universities/Institutes, H1 2015 36
Glaucoma - Pipeline by AC Immune SA, H1 2015 37
Glaucoma - Pipeline by Acadia Pharmaceuticals Inc., H1 2015 38
Glaucoma - Pipeline by Aerie Pharmaceuticals, Inc., H1 2015 39
Glaucoma - Pipeline by Alcon, Inc., H1 2015 40
Glaucoma - Pipeline by Allergan, Inc., H1 2015 41
Glaucoma - Pipeline by Altacor Ltd., H1 2015 42
Glaucoma - Pipeline by Amakem NV, H1 2015 43
Glaucoma - Pipeline by Asahi Kasei Pharma Corp., H1 2015 44
Glaucoma - Pipeline by AUS Bio Limited, H1 2015 45
Glaucoma - Pipeline by Bausch & Lomb Incorporated, H1 2015 46
Glaucoma - Pipeline by Bionure Farma, S.L., H1 2015 47
Glaucoma - Pipeline by Can-Fite BioPharma Ltd., H1 2015 48
Glaucoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2015 49
Glaucoma - Pipeline by China Grand Wuhan General Pharmaceutical Research Institute, H1 2015 50
Glaucoma - Pipeline by D. Western Therapeutics Institute, Inc., H1 2015 51
Glaucoma - Pipeline by DNAVEC Corporation, H1 2015 52
Glaucoma - Pipeline by Dompe Farmaceutici S.p.A., H1 2015 53
Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 54
Glaucoma - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 55
Glaucoma - Pipeline by Gene Signal International SA, H1 2015 56
Glaucoma - Pipeline by Gilead Sciences, Inc., H1 2015 57
Glaucoma - Pipeline by Handok Inc., H1 2015 58
Glaucoma - Pipeline by High Point Pharmaceuticals, LLC, H1 2015 59
Glaucoma - Pipeline by Icon Bioscience, Inc., H1 2015 60
Glaucoma - Pipeline by IMMD Inc., H1 2015 61
Glaucoma - Pipeline by Inotek Pharmaceuticals Corporation, H1 2015 62
Glaucoma - Pipeline by InSite Vision Incorporated, H1 2015 63
Glaucoma - Pipeline by Lacer, S.A., H1 2015 64
Glaucoma - Pipeline by Merck & Co., Inc., H1 2015 65
Glaucoma - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2015 66
Glaucoma - Pipeline by Mimetogen Pharmaceuticals Inc., H1 2015 67
Glaucoma - Pipeline by NeoStem, Inc., H1 2015 68
Glaucoma - Pipeline by Neurotech Pharmaceuticals, Inc., H1 2015 69
Glaucoma - Pipeline by NicOx S.A., H1 2015 70
Glaucoma - Pipeline by Ocata Therapeutics, Inc., H1 2015 71
Glaucoma - Pipeline by Ocular Therapeutix, Inc., H1 2015 72
Glaucoma - Pipeline by Ohr Pharmaceutical Inc., H1 2015 73
Glaucoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 74
Glaucoma - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 75
Glaucoma - Pipeline by Oxford BioMedica plc, H1 2015 76
Glaucoma - Pipeline by PharmaNova Inc., H1 2015 77
Glaucoma - Pipeline by Quark Pharmaceuticals, Inc., H1 2015 78
Glaucoma - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2015 79
Glaucoma - Pipeline by Senju Pharmaceutical Co., Ltd., H1 2015 80
Glaucoma - Pipeline by SIFI S.p.A, H1 2015 81
Glaucoma - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 82
Glaucoma - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 83
Glaucoma - Pipeline by Sylentis S.A., H1 2015 84
Glaucoma - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 85
Glaucoma - Pipeline by Upsher-Smith Laboratories, Inc., H1 2015 86
Assessment by Monotherapy Products, H1 2015 87
Assessment by Combination Products, H1 2015 88
Number of Products by Stage and Target, H1 2015 90
Number of Products by Stage and Mechanism of Action, H1 2015 94
Number of Products by Stage and Route of Administration, H1 2015 98
Number of Products by Stage and Molecule Type, H1 2015 100
Glaucoma Therapeutics - Recent Pipeline Updates, H1 2015 216
Glaucoma - Dormant Projects, H1 2015 237
Glaucoma - Discontinued Products, H1 2015 239 



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify